Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. more
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -1.72% | 0.39% |
| 1-Month Return | -7.36% | -0.73% |
| 3-Month Return | 11.17% | 3.21% |
| 6-Month Return | 16.44% | 6.58% |
| 1-Year Return | 125.35% | 17.34% |
| 3-Year Return | 102.66% | 62.07% |
| 5-Year Return | 9.49% | 69.46% |
| 10-Year Return | 141.47% | 242.52% |
| Time Frame | BBC | S&P500 |
|---|---|---|
| 1-Week Return | -59.53% | 22.50% |
| 1-Month Return | -60.55% | -8.53% |
| 3-Month Return | 53.64% | 13.67% |
| 6-Month Return | 36.16% | 13.79% |
| 1-Year Return | 125.35% | 17.34% |
| 3-Year Return | 26.55% | 17.46% |
| 5-Year Return | 1.83% | 11.13% |
| 10-Year Return | 9.22% | 13.10% |
| Stock name | Ticker | Weight |
|---|---|---|
First Tracks Biotherapeutics Inc | TRAX | 1.76% |
Monopar Therapeutics Inc | MNPR | 1.25% |
MBX Biosciences Inc | MBX | 1.22% |
AtaiBeckley Inc | ATAI | 1.19% |
Definium Therapeutics Inc | DFTX | 1.17% |
Xencor Inc | XNCR | 1.13% |
Zenas Biopharma Inc | ZBIO | 1.06% |
uniQure NV | QURE | 1% |
Apogee Therapeutics Inc | APGE | 0.99% |
REGENXBIO Inc | RGNX | 0.99% |
Vor BioPharma Inc | VOR | 0.99% |
LB Pharmaceuticals Inc | LBRX | 0.94% |
Amylyx Pharmaceuticals Inc | AMLX | 0.92% |
Dyne Therapeutics Inc | DYN | 0.92% |
ORIC Pharmaceuticals Inc | ORIC | 0.92% |
Damora Therapeutics Inc | DMRA | 0.91% |
Oruka Therapeutics Inc | ORKA | 0.91% |
Nurix Therapeutics Inc | NRIX | 0.9% |
Palvella Therapeutics Inc | PVLA | 0.9% |
BioAge Labs Inc | BIOA | 0.9% |
Dianthus Therapeutics Inc | DNTH | 0.89% |
GH Research PLC | GHRS | 0.87% |
Alto Neuroscience Inc | ANRO | 0.87% |
Erasca Inc | ERAS | 0.86% |
SELLAS Life Sciences Group Inc | SLS | 0.85% |
Avalo Therapeutics Inc | AVTX | 0.85% |
Relay Therapeutics Inc | RLAY | 0.85% |
Jade Biosciences Inc | JBIO | 0.85% |
Sionna Therapeutics Inc | SION | 0.85% |
Cullinan Therapeutics Inc | CGEM | 0.83% |
Adlai Nortye Ltd | ANL | 0.82% |
Spyre Therapeutics Inc | SYRE | 0.82% |
Ideaya Biosciences Inc | IDYA | 0.82% |
Immunome Inc | IMNM | 0.82% |
Cogent Biosciences Inc | COGT | 0.81% |
MeiraGTx Holdings plc | MGTX | 0.81% |
Revolution Medicines Inc | RVMD | 0.81% |
Kodiak Sciences Inc | KOD | 0.81% |
Monte Rosa Therapeutics Inc | GLUE | 0.81% |
Kymera Therapeutics Inc | KYMR | 0.81% |
Xenon Pharmaceuticals Inc | XENE | 0.8% |
SpyGlass Pharma Inc | SGP | 0.8% |
Celldex Therapeutics Inc | CLDX | 0.8% |
CG oncology Inc | CGON | 0.8% |
Biohaven Ltd | BHVN | 0.8% |
Tyra Biosciences Inc | TYRA | 0.8% |
Rezolute Inc | RZLT | 0.79% |
Lexicon Pharmaceuticals Inc | LXRX | 0.79% |
Viridian Therapeutics Inc | VRDN | 0.79% |
Sana Biotechnology Inc | SANA | 0.79% |
Bicara Therapeutics Inc | BCAX | 0.79% |
Nektar Therapeutics | NKTR | 0.78% |
Alumis Inc | ALMS | 0.78% |
Olema Pharmaceuticals Inc | OLMA | 0.78% |
Solid Biosciences Inc | SLDB | 0.77% |
Arcus Biosciences Inc | RCUS | 0.77% |
Edgewise Therapeutics Inc | EWTX | 0.77% |
Vaxcyte Inc | PCVX | 0.77% |
Immunovant Inc | IMVT | 0.76% |
Enliven Therapeutics Inc | ELVN | 0.76% |
Rocket Pharmaceuticals Inc | RCKT | 0.76% |
Disc Medicine Inc | IRON | 0.76% |
Belite Bio Inc | BLTE | 0.75% |
Neurogene Inc | NGNE | 0.75% |
Praxis Precision Medicines Inc | PRAX | 0.75% |
Candel Therapeutics Inc | CADL | 0.75% |
Structure Therapeutics Inc | GPCR | 0.75% |
Viking Therapeutics Inc | VKTX | 0.75% |
Design Therapeutics Inc | DSGN | 0.75% |
Janux Therapeutics Inc | JANX | 0.75% |
Maze Therapeutics Inc | MAZE | 0.75% |
Altimmune Inc | ALT | 0.74% |
Achieve Life Sciences Inc | ACHV | 0.74% |
4D Molecular Therapeutics Inc | FDMT | 0.74% |
Assembly Biosciences Inc | ASMB | 0.74% |
Generate Biomedicines Inc | GENB | 0.74% |
Annexon Inc | ANNX | 0.73% |
Rapport Therapeutics Inc | RAPP | 0.72% |
Aura Biosciences Inc | AURA | 0.72% |
Scholar Rock Holding Corp | SRRK | 0.72% |
Mineralys Therapeutics Inc | MLYS | 0.72% |
Corvus Pharmaceuticals Inc | CRVS | 0.72% |
Pharvaris NV | PHVS | 0.72% |
BridgeBio Oncology Therapeutics Inc | BBOT | 0.71% |
Arvinas Inc | ARVN | 0.71% |
CytomX Therapeutics Inc | CTMX | 0.71% |
VeraDermics Inc | MANE | 0.71% |
Prime Medicine Inc | PRME | 0.71% |
AbCellera Biologics Inc | ABCL | 0.71% |
Upstream Bio Inc | UPB | 0.7% |
Climb Bio Inc | CLYM | 0.69% |
Savara Inc | SVRA | 0.68% |
Aktis Oncology Inc | AKTS | 0.68% |
Allogene Therapeutics Inc | ALLO | 0.67% |
Arbutus Biopharma Corp | ABUS | 0.67% |
Vir Biotechnology Inc | VIR | 0.67% |
Taysha Gene Therapies Inc | TSHA | 0.67% |
Prothena Corp PLC | PRTA | 0.66% |
MoonLake Immunotherapeutics | MLTX | 0.66% |
Immix Biopharma Inc | IMMX | 0.66% |
Oculis Holding AG | OCS | 0.66% |
Stoke Therapeutics Inc | STOK | 0.66% |
ArriVent Biopharma Inc | AVBP | 0.65% |
Lexeo Therapeutics Inc | LXEO | 0.65% |
Bicycle Therapeutics PLC | BCYC | 0.64% |
Celcuity Inc | CELC | 0.64% |
EyePoint Inc | EYPT | 0.64% |
AnaptysBio Inc | ANAB | 0.64% |
WaVe Life Sciences Ltd | WVE | 0.64% |
Immatics NV | IMTX | 0.64% |
Septerna Inc | SEPN | 0.64% |
Recursion Pharmaceuticals Inc | RXRX | 0.63% |
Vera Therapeutics Inc | VERA | 0.63% |
ProKidney Corp | PROK | 0.63% |
Summit Therapeutics Inc | SMMT | 0.62% |
Compass Pathways Plc | CMPS | 0.62% |
Compass Therapeutics Inc | CMPX | 0.62% |
Tectonic Therapeutic Inc | TECX | 0.61% |
Newamsterdam Pharma Co NV | NAMS | 0.61% |
Inhibrx Biosciences Inc | INBX | 0.6% |
Intellia Therapeutics Inc | NTLA | 0.6% |
Beam Therapeutics Inc | BEAM | 0.59% |
Cabaletta Bio Inc | CABA | 0.59% |
Tango Therapeutics Inc | TNGX | 0.58% |
Crescent Biopharma Inc | CBIO | 0.55% |
Relmada Therapeutics Inc | RLMD | 0.52% |
Invivyd Inc | IVVD | 0.49% |
Replimune Group Inc | REPL | 0.4% |
Evommune Inc | EVMN | 0.37% |
MapLight Therapeutics Inc | MPLT | 0.33% |
Cash/Cash equivalents | Cash.Cash.equivalents | 0.15% |
Capricor Therapeutics Inc | CAPR | 0.11% |
| Sector | Weight |
|---|---|
|
Health care | 100.00% |
Virtus LifeSci Biotech Clinical Trials ETF (BBC) share price today is $48.7362.
Yes, Indians can buy shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. To buy BBC from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Virtus LifeSci Biotech Clinical Trials ETF (BBC) on Vested. You can start investing in Virtus LifeSci Biotech Clinical Trials ETF (BBC) with a minimum investment of $1.
The 52-week high price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $54.95. The 52-week low price of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is $20.52.
The stock symbol (or ticker) of Virtus LifeSci Biotech Clinical Trials ETF is BBC.
Yes, you can setup SIP in Virtus LifeSci Biotech Clinical Trials ETF shares. Follow the below steps to create the SIP:
Here is the historical performance of BBC on the Vested app.
The expense ratio of Virtus LifeSci Biotech Clinical Trials ETF (BBC) is 0.79%.
Link copied